Contact Us

For General Enquiries:

1 Kingdom Street
London
W2 6BD
United Kingdom

Tel: +44 (0)1256 894003

 

For Medical Information or to Report Suspected Side Effects:

Shire Pharmaceuticals Limited:

  • BUCCOLAM® (midazolam oromucosal solution) SPC PIL
  • CINRYZE® (C1 esterase inhibitor [human]) SPC PIL
  • DIAMORPHINE HYDROCHLORIDE BP® (diamorphine hydrochloride) SPC PIL
  • ELAPRASE® (idursulfase) SPC PIL
  • ELVANSE® (lisdexamfetamine dimesylate) SPC PIL
  • EQUASYM XL® (methylphenidate hydrochloride) SPC PIL
  • FIRAZYR® (icatibant) SPC PIL
  • FOSRENOL® (lanthanum carbonate) SPC PIL
  • MEZAVANT® (mesalamine) SPC PIL
  • PLENADREN® (hydrocortisone modified-release tablets) SPC PIL
  • REMINYL® (galantamine hydrobromide) SPC PIL
  • REPLAGAL® (agalsidase alfa) SPC PIL
  • RESOLOR® (prucalopride succinate) SPC PIL
  • VPRIV® (velaglucerase alfa for injection) SPC PIL 
  • XAGRID® (anagrelide hydrochloride) SPC PIL

Medical Information:
Tel: +44 (0)800 055 6614
Email: medinfoEMEA@shire.com

To Report Suspected Side Effects:
Tel: +44(0)1256 894000
Fax: +44(0)1256 894715Email: globalpharmacovigilance@shire.com

Customer Service:
Sales/Product Enquiries Customer Support Line:
Tel: +44(0)1256 894107

For invoices and payment advice:
Tel: +44(0)1256 894000

For Baxalta related products:

Medical Information:
Tel: +44 (0)800 055 6614
Email: medinfoEMEA@shire.com

To Report Suspected Side Effects:
Tel: +44 (0) 20 3655 2430
Email: pvuknordic@baxalta.com
Reporting forms and information:
mhra.gov.uk/yellowcard

Adverse events (suspected side effects) should be reported. Healthcare professionals are asked to report any suspected adverse events via the Yellow Card Scheme. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

EFPIA

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. EFPIA believes that interactions between the pharmaceutical industry and healthcare professionals have a profound and positive influence on the quality of patient treatment and the value of future research.

Shire supports the principles of transparency put forth by EFPIA, is reporting based on local disclosure codes, and is committed to ensure that we meet the high standards of integrity that patients, governments and other stakeholders expect.

Below is a link to Shire’s EFPIA disclosure reports: https://www.shire.com/who-we-are/how-we-operate/efpia-reporting